PregnancyLAMBSNCT02140879
LA Moms and Babies Study (LAMBS) for Nutrition and Growth
A study testing Capsule 1 or Capsule 2 and Capsule 2 in people with Pregnancy and Inflammation, run by Pennington Biomedical Research Center at 1 site in United States.
Trial summary
This research study will examine how diet during pregnancy can benefit pregnancy and pregnancy outcome, such as your baby's weight. More specifically, the investigators will study the effects of two different food oils/fats that are commonly consumed to determine if one is more effective in limiting maternal… Read more about this study
- Who is it for?
- Ages 18 to 35 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Pregnancy, Inflammation
- What is being tested?
- Capsule 1 or Capsule 2 and Capsule 2
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2014to Aug 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Confirmed pregnancy
- Caucasian/White and African-American ethnicities
- Between the ages of 18 and 35 years
- Overweight before becoming pregnant (BMI=25.0-29.9 kg/m2)
- Pass on the glucose tolerance test for diabetes
Who cannot join
- Have more than 5 children
- Have a history of high blood pressure, high blood lipids, kidney or liver disease
- Have inability to handle blood sugar normally
- Have polycystic ovary syndrome
- Have thyroid disorder
- Have multiple fetuses, pregnancy related complications (preterm labor; diagnosed with gestational diabetes mellitus, pregnancy impaired glucose tolerance, preeclampsia, a first degree relative with diabetes, gave birth to a previous large for gestational age infanthigh blood pressure, premature rupture of the membranes)
Show all 15Show fewer
- Have smoked in the past 6 months
- Have been pregnant or lactating (breastfeeding) in the past year
- Do not want their baby's body fat measured throughout the first year of life
- Do not bring their prenatal record and study information copies to Woman's Hospital for delivery
- Deliver at a hospital other than Woman's Hospital
- Test positive for human immunodeficiency Virus (HIV), syphilis, sepsis, group B streptococcus, Hepatitis B
- Do not follow study procedures
- Planning to bank cord blood or unwilling to donate cord blood
- Planned/elective C-section.
Trial locations and contacts
1 site in 1 country.
About this study
This research study will examine how diet during pregnancy can benefit pregnancy and pregnancy outcome, such as your baby's weight. More specifically, the investigators will study the effects of two different food oils/fats that are commonly consumed to determine if one is more effective in limiting maternal inflammation during pregnancy. You are being asked to take part in this study because it will help us update and make the best dietary recommendations for pregnant women and women of child bearing ages.
Read the detailed description
Pregnant women will be asked to consume dietary supplements (2 capsules, from the Pennington Biomedical Pharmacy) each day during pregnancy. They will begin taking the capsules around 17 weeks of pregnancy and take them each day until their babies are born. Women will be randomized to one of two groups. Randomization means they will be put into a group by chance, similar to flipping a coin. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. Neither the subject nor the study staff will know which group women are in.
Women will also keep a diary of how many capsules they take. At around 17, 22, 24, 26, 30, 32, and 36 weeks of pregnancy, women will go to Woman's Hospital to get new capsules and return any remaining capsules and their capsule diary. If they are not able to go to Woman's Hospital at weeks 22, 26, or 32 a researcher will arrange to meet them at an agreed upon prearranged place, such as a pharmacy, a library, or Pennington Biomedical, for example. At the same visits to Woman's Hospital at weeks 17, 24, 30, and 36 weeks of pregnancy women will also have their blood drawn (approximately one tablespoon).
At 17, 22, 24, 26, 30, 32 and 36 weeks of pregnancy we will also ask women about the foods they are eating. We will do this by a prearranged phone call; women will not need to meet us in person for this.
Researchers will contact subjects weekly by phone to inquire about compliance with consumption of capsules. Contact will only take place during weeks in which a visit or phone call regarding diet is not required.
At 17, 24, 30, and 36 weeks of pregnancy small blood samples will be collected from their arm (approximately one tablespoon at each collection) for laboratory analyses. At the birth of their baby a sample of blood will be collected from the umbilical cord after their baby is delivered. All blood samples will be stored at Pennington Biomedical. Blood samples will be analyzed by the researchers who are involved in the study. Some analyses will take place at Pennington Biomedical and Louisiana State University (LSU). Deidentified (without subject names) samples will be sent to study researchers at Northeastern University in Boston, LSU Health Sciences Center in New Orleans, and DSM Nutritional Products in Columbia, Maryland for some of the analyses. At the end of the study remaining blood samples will be discarded unless women consent for their blood to be used for future research. Should women decide to withdraw from the study, any samples collected thus far will be included in the study since they will be deidentified and the investigators will not know which samples belong to each person. We will also collect information about the baby's birth weight, length, and health from the baby's hospital chart.
When the baby is 2 weeks, 6 months, and 12 months of age we will measure the baby's body fat and lean tissue. To do this measurement the baby will lie or sit in an enclosed chamber where the mother can see her baby during the measurements. There are no attachments made to the baby. At these times we will also determine the baby's body fat by measuring the thickness of the baby's skinfold; this is done by gently lifting a double fold of skin on the baby's hip, upper arm (triceps), and back of the thigh and measuring the thickness of that fold with a handheld instrument with two hinged arms that fit over the skinfold. There is no discomfort associated with this procedure. The measurements will be made at Woman's Hospital. During these visits we will also ask questions about how the mother is feeding her baby. Between these visits (when the baby is 2, 4, 8, and 10 months old) we will phone to ask about how the baby is being fed and to inquire about the mother's and baby's well-being.
- Conditions
- Pregnancy, Inflammation
- Being tested
- Capsule 1 or Capsule 2, Capsule 2
- Keywords
- pregnancy, inflammation, infant assessment
- Medical subject headings
- Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Capsule 1 or Capsule 2Dietary supplement
Capsules will be consumed on a daily basis during pregnancy. One group, the placebo group of the study, will take capsules (2/day) containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets.
Capsule 2Dietary supplement
Two capsules will be consumed on a daily basis during pregnancy. The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils .
| Study group | Role | What they receive |
|---|---|---|
| Capsule 1 | Placebo comparator | Placebo is a mixture of corn and soy oils. Receives: Dietary Supplement: Capsule 1 or Capsule 2; Dietary Supplement: Capsule 2 |
| Capsule 2 | Active comparator | Active supplement group, will take capsules containing oil '2' which is an algal oil. Receives: Dietary Supplement: Capsule 1 or Capsule 2; Dietary Supplement: Capsule 2 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Differences in maternal inflammation between the two study groups.
Pregnancy creates a state of insulin resistance that is worsened by excess weight during pregnancy and it is accompanied by inflammation. Inflammation in pregnant women will be measured by a blood draw from the arm and analysis of the blood.
Measured: The Participant will be followed during pregnancy, between the 17th and 36th week of pregnancy, on average of 19 weeks.
Secondary outcomes (1)
Differences in infant growth will be determined with measurements of infant height and weight and with an instrument that determines air displaced by the baby's body.
Measurements of the baby will be calculated in an enclosed chamber where the baby will lie on a tray in a bassinet-like crib with a plastic cover where the baby will be able to see his mother. There will be no attachments to the baby. At these time periods the baby's body fat will also be measured by the thickness of the baby's skinfold; this is done by gently lifting a double fold of skin on the baby's hip, upper arm (triceps), and back of the thigh and measuring the thickness of that fold with a handheld instrument with two hinged arms that fit over the skinfold. There is no discomfort associated with this procedure.
Measured: The participant will be followed the First year of life, an expected average of 52 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 May 2014 (estimated)
- Study startApr 2014
- Primary completionApr 2016
- Study completionAug 2017
Why it stopped: IRB closed on 9/5/2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PregnancyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pennington Biomedical Research Center
- Sponsor type
- University, hospital or other
- Collaborators
- United States Department of Agriculture (USDA)
- Responsible party
- Sponsor
- Investigators
- Carol J Lammi-Keefe, PhD, RD, Principal investigator, PBRC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02140879
- Sponsor's protocol ID
- PBRC 11031
- Acronym
- LAMBS
- Status last verified
- Sep 2022
- First submitted
- 24 Apr 2014
- Last updated
- 15 Sep 2022
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- LA Moms and Babies Study (LAMBS) for Nutrition and Growth
- ClinicalTrials.gov ID
- NCT02140879
- Acronym / sponsor ID
- LAMBS / PBRC 11031
- Conditions
- Pregnancy, Inflammation
- Keywords
- pregnancy, inflammation, infant assessment
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: IRB closed on 9/5/2018
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Pennington Biomedical Research CenterUniversity, hospital or other
- Collaborators
- United States Department of Agriculture (USDA)
- Study start
- Apr 2014 (actual)
- Primary completion
- Apr 2016 (actual)
- Study completion
- Aug 2017 (actual)
- First posted
- 16 May 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This research study will examine how diet during pregnancy can benefit pregnancy and pregnancy outcome, such as your baby's weight. More specifically, the investigators will study the effects of two different food oils/fats that are commonly consumed to determine if one is more effective in limiting maternal inflammation during pregnancy. You are being asked to take part in this study because it will help us update and make the best dietary recommendations for pregnant women and women of child bearing ages.
Detailed description
Pregnant women will be asked to consume dietary supplements (2 capsules, from the Pennington Biomedical Pharmacy) each day during pregnancy. They will begin taking the capsules around 17 weeks of pregnancy and take them each day until their babies are born. Women will be randomized to one of two groups. Randomization means they will be put into a group by chance, similar to flipping a coin. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. Neither the subject nor the study staff will know which group women are in.
Women will also keep a diary of how many capsules they take. At around 17, 22, 24, 26, 30, 32, and 36 weeks of pregnancy, women will go to Woman's Hospital to get new capsules and return any remaining capsules and their capsule diary. If they are not able to go to Woman's Hospital at weeks 22, 26, or 32 a researcher will arrange to meet them at an agreed upon prearranged place, such as a pharmacy, a library, or Pennington Biomedical, for example. At the same visits to Woman's Hospital at weeks 17, 24, 30, and 36 weeks of pregnancy women will also have their blood drawn (approximately one tablespoon).
At 17, 22, 24, 26, 30, 32 and 36 weeks of pregnancy we will also ask women about the foods they are eating. We will do this by a prearranged phone call; women will not need to meet us in person for this.
Researchers will contact subjects weekly by phone to inquire about compliance with consumption of capsules. Contact will only take place during weeks in which a visit or phone call regarding diet is not required.
At 17, 24, 30, and 36 weeks of pregnancy small blood samples will be collected from their arm (approximately one tablespoon at each collection) for laboratory analyses. At the birth of their baby a sample of blood will be collected from the umbilical cord after their baby is delivered. All blood samples will be stored at Pennington Biomedical. Blood samples will be analyzed by the researchers who are involved in the study. Some analyses will take place at Pennington Biomedical and Louisiana State University (LSU). Deidentified (without subject names) samples will be sent to study researchers at Northeastern University in Boston, LSU Health Sciences Center in New Orleans, and DSM Nutritional Products in Columbia, Maryland for some of the analyses. At the end of the study remaining blood samples will be discarded unless women consent for their blood to be used for future research. Should women decide to withdraw from the study, any samples collected thus far will be included in the study since they will be deidentified and the investigators will not know which samples belong to each person. We will also collect information about the baby's birth weight, length, and health from the baby's hospital chart.
When the baby is 2 weeks, 6 months, and 12 months of age we will measure the baby's body fat and lean tissue. To do this measurement the baby will lie or sit in an enclosed chamber where the mother can see her baby during the measurements. There are no attachments made to the baby. At these times we will also determine the baby's body fat by measuring the thickness of the baby's skinfold; this is done by gently lifting a double fold of skin on the baby's hip, upper arm (triceps), and back of the thigh and measuring the thickness of that fold with a handheld instrument with two hinged arms that fit over the skinfold. There is no discomfort associated with this procedure. The measurements will be made at Woman's Hospital. During these visits we will also ask questions about how the mother is feeding her baby. Between these visits (when the baby is 2, 4, 8, and 10 months old) we will phone to ask about how the baby is being fed and to inquire about the mother's and baby's well-being.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Capsule 1 | Placebo comparator | Dietary Supplement: Capsule 1 or Capsule 2, Dietary Supplement: Capsule 2Placebo is a mixture of corn and soy oils. |
| Capsule 2 | Active comparator | Dietary Supplement: Capsule 1 or Capsule 2, Dietary Supplement: Capsule 2Active supplement group, will take capsules containing oil '2' which is an algal oil. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Confirmed pregnancy
- Caucasian/White and African-American ethnicities
- Between the ages of 18 and 35 years
- Overweight before becoming pregnant (BMI=25.0-29.9 kg/m2)
- Pass on the glucose tolerance test for diabetes
Key exclusion criteria (15 listed)
- Have more than 5 children
- Have a history of high blood pressure, high blood lipids, kidney or liver disease
- Have inability to handle blood sugar normally
- Have polycystic ovary syndrome
- Have thyroid disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Capsule 1 or Capsule 2Capsules will be consumed on a daily basis during pregnancy. One group, the placebo group of the study, will take capsules (2/day) containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. | Dietary supplement | Capsule 1, Capsule 2 |
| Capsule 2Two capsules will be consumed on a daily basis during pregnancy. The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils . | Dietary supplement | Capsule 1, Capsule 2 |
Primary outcome
Differences in maternal inflammation between the two study groups.
Time frame: The Participant will be followed during pregnancy, between the 17th and 36th week of pregnancy, on average of 19 weeks.
Pregnancy creates a state of insulin resistance that is worsened by excess weight during pregnancy and it is accompanied by inflammation. Inflammation in pregnant women will be measured by a blood draw from the arm and analysis of the blood.
1 secondary outcome
Differences in infant growth will be determined with measurements of infant height and weight and with an instrument that determines air displaced by the baby's body.
Time frame: The participant will be followed the First year of life, an expected average of 52 weeks.
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2022.
Related trials for Pregnancy
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carol J Lammi-Keefe, PhD, RD principal investigator
PBRC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Capsule 1 or Capsule 2 and Capsule 2 in people with Pregnancy and Inflammation, run by Pennington Biomedical Research Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 15 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Differences in maternal inflammation between the two study groups. (time frame: The Participant will be followed during pregnancy, between the 17th and 36th week of pregnancy, on average of 19 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2022.